Here's the Deal
Baird's Investment Banking Group is pleased to announce the following transaction:
Robert W. Baird & Co. acted as co-manager on this transaction.
TomoTherapy Incorporated (NASDAQ: TTPY) recently announced a follow-on offering of 9,775,000 shares (including over-allotment option) of its common stock at $22.25 a share, for gross proceeds of $217.5 million. All the proceeds of this offering will be received by the selling shareholders.
TomoTherapy (the “Company”) develops, manufactures and sells the Hi Art system, an advanced and versatile radiation therapy system for the treatment of a wide range of cancer types. The Hi Art system combines integrated CT imaging with radiation therapy to deliver radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue, which the Company believes can lead to improved patient outcomes. The Hi Art system contains a linear accelerator, which is a device that generates external beam radiation that is used both to capture high quality, quantitative images and to deliver therapeutic radiation in a helical, or spiral, delivery pattern 360 degrees around the body.
The Hi Art system’s helical delivery pattern and imaging capabilities, combined with the system’s advanced treatment planning software and ability to precisely shape the beam delivering radiation, allow clinicians to locate and define the size, shape and density of tumors, maximize radiation delivered to diseased tissue, minimize radiation delivered to healthy tissue and measure the radiation dose actually received by the patient.
The Baird team included our dedicated Healthcare industry bankers and members of our Equity Capital Markets Group.